Smoking Cessation
Conditions
Keywords
Pharmacotherapy, Titration, Smoking Cessation
Brief summary
The primary aim of this research study is to determine whether titrated, patient-directed transdermal patch NRT, based on smoking history and symptoms of nicotine withdrawal, improves long-term rates of smoking cessation in patients motivated to quit smoking when compared to patients using the standard transdermal NRT patch protocol. The following hypothesis will be tested: CO-validated continuous abstinence rate at 52 weeks post target quit date will be higher for the titrated, self-directed NRT group compared to the standard NRT treatment group.
Detailed description
Participants will be recruited from the UOHI Smoking Cessation Clinic and via media advertisements. Following their baseline assessment, participants will be randomly assigned to one of two groups: 1. 10-week standard treatment of transdermal nicotine replacement therapy (NRT);or 2. 10-week titrated transdermal nicotine replacement therapy (NRT) treatment with additional NRT product (NRT+) Participants assigned to the "NRT" standard treatment group will follow a 10-week regimen of nicotine patches alone. Participants assigned to the "NRT+" titrated treatment group will follow a 10-week regimen of tailored patch dosage. Participants will also be provided with the Nicorette inhaler. All participants will receive five 15-minute counselling sessions from a smoking cessation counsellor. These sessions occur at 1, 3, 5, 8 and 10 weeks post target quit date. Counselling sessions will focus on practical counselling (problem solving and skills training) and social support. During the treatment phase, participants will complete questionnaires measuring withdrawal symptoms, self-efficacy, use of cessation resources and the Beck Depression Inventory (BDI-II) at weeks 1, 3, 5, 8 and 10. These questionnaires will also be completed at 26 and 52 weeks post target quit date.
Interventions
DRUGNicoDerm Patch
Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period \*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.
DRUGNicorette Inhaler
Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
Sponsors
Ottawa Heart Institute Research Corporation
Heart and Stroke Foundation of Ontario
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Current smoker (≥ 10 cigarette per day); 2. 18 years of age or older; 3. Willing to set a date to quit smoking within the 30 days following the baseline assessment; 4. Participant is willing to return to the UOHI for follow-up examination; 5. Participant is willing to provide informed consent; 6. Motivated to quit smoking.
Exclusion criteria
1. Participant is unable to read and understand English or French; 2. Participant is pregnant, lactating or planning to become pregnant during the study period; 3. Participant has attempted to quit smoking in the previous month with the support of medication for \>72 hours; 4. Participant is currently using a smoking cessation medication (e.g., NRT, Bupropion, Varenicline,Clonadine, Notriptyline); 5. Participant has contraindication(s) to nicotine replacement therapy (allergy to adhesive, life-threatening arrhythmias (e.g., tachycardia); 6. Participant is during the immediate post-myocardial infarction period (i.e. incident has occurred within the last 10 days); 7. Severe or worsening angina pectoris; 8. Subject has had a recent cerebral vascular accident (i.e. incident has occurred within the last 10 days); 9. Participant currently suffering with depression (BDI-II ≥20); 10. Participant who has been diagnosed with depression or treated with an antidepressant in the past 12 months; 11. Past or present history of psychosis (Schizophrenia, Schizophreniform or Delusional Disorders),panic disorder, or bipolar disorder; 12. Drug or alcohol abuse or dependence in the past year; 13. Member of the participant's household is already participating in the study or in the "Quit Smoking in the 'Real World'" study; 14. Participant is currently participating in or already receiving counseling or follow-up for smoking cessation. 13.) Participants who in the opinion of the investigator will be unlikely to commit to a year-long study;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validated Continuous Abstinence Rate at Week 52 | Week 52 | Self-reported continuous abstinence at week 52 post target quit date will be confirmed with a carbon monoxide breath test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Validated Continuous Abstinence Rates at Weeks 10 and 26 Weeks | weeks 10, 26 | Self-reported continuous abstinence rates will be validated with a carbon monoxide breath test at weeks 10 and 26 post target quit date. |
| Self Reported 7-day Point Prevalence at Weeks 10, 26 and 52. | Self-reported seven day point prevalence of abstinence will be validated at week 10, 26 and 52 weeks post target quite date. | — |
| Self-reported Continuous Abstinence at Weeks 10, 26 and 52 | Week 1 to 52 | — |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATORAndrew Pipe, CM, MD
Ottawa Heart Institute Research Corporation
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 47.4 Years STANDARD_DEVIATION 10.9 |
| Baseline BMI | 28.4 Kg/m^2 STANDARD_DEVIATION 5.7 |
| Cigarettes smoked per day in the past month | 23.3 cigarettes per day STANDARD_DEVIATION 7.6 |
| Duration of Smoking | 29.0 Years STANDARD_DEVIATION 11.7 |
| Fagerstrom Test for Nicotine Dependence (FTCD) Score | 5.8 Scores on a scale STANDARD_DEVIATION 2.2 |
| Formal Education | 14.2 Years of formal education STANDARD_DEVIATION 2.7 |
| Household Income <$20,000 per year | 52 Participants |
| Household Income $20,000 to $59,999 | 97 Participants |
| Household Income >$60,000 | 61 Participants |
| Household Income Unknown (missing or prefer not to say) | 28 Participants |
| Number of quit attempts in the past year | 4.3 quit attempts STANDARD_DEVIATION 5.6 |
| Race and Ethnicity Not Collected | 0 Participants |
| Sex: Female, Male Female | 57 Participants |
| Sex: Female, Male Male | 97 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 149 | 0 / 149 |
| other Total, other adverse events | 2 / 149 | 0 / 149 |
| serious Total, serious adverse events | 0 / 149 | 0 / 149 |
Outcome results
None listed